Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I21RX003464-01A1 |
| Title: | NICOTINAMIDE RIBOSIDE FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NEUROPATHY, DRY EYE SYNDROME, AND HEARING LOSS |
| Principal Investigator: | Marta Hamity |
| Location: | Iowa City, IA |
| Congressional District Code: | 2 |
| Research Service: | Rehabilitation R&D |
| Project Period: | September 2020 - August 2022 |
| FY 2021 Funding Amount: | $100,321 |
| Total Award Amount (all years): |
$199,423 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Continuing advances in detection and treatment have greatly increased the number of cancer survivors, as well as more Veterans living with cancer because of continued therapy. However, while these therapies prolong life, they are accompanied by adverse effects that introduce functional limitations and significantly reduce quality of life of Veterans. For example, taxane and platinum-based chemotherapies produce very painful and debilitating peripheral neuropathies that greatly diminish patients’... |